ScripBiocad has received a go-ahead from a key expert panel in India for infliximab, its biosimilar version of Johnson & Johnson 's Remicade, amid some confusing signals on the Russian firm’s potential la
Generics BulletinThe initial market for biosimilars has centered on large-market opportunities like Genentech’s Rituxan and AbbVie’s Humira . But behind that first wave are unique opportunities in much smaller mark
Pink SheetThe initial market for biosimilars has centered on large-market opportunities like Genentech’s Rituxan and AbbVie’s Humira . But behind that first wave are unique opportunities in much smaller mark
In VivoThe establishment of a regulatory approval pathway in the US – via the enactment of the Biologics Price Competition and Innovation Act of 2009 as part of the Affordable Care Act – has given way to app